603233.SHG Dashenlin Pharm Grp Co Ltd
- Market cap
- CNY 24.2B
- P/E
- 16.8x
- P/B
- 3.25x
- ROE
- 22.3%
- Dividend yield
- 3.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603233.SHG undervalued?
Graham number603233.SHG trades 55.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dashenlin Pharm Grp Co Ltd fundamental analysis
No fundamental analysis for Dashenlin Pharm Grp Co Ltd yet.
Dashenlin Pharm Grp Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. engages in the manufacture, distribution, and retail of pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and tonic herbs, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
Full company profileDashenlin Pharm Grp Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dashenlin Pharm Grp Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.27B | 7.42B | 8.86B | 11.1B | 14.6B | 16.8B | 21.2B | 24.5B | 26.5B | 27.5B | 28.4B |
| Gross Profit | 2.52B | 2.98B | 3.68B | 4.39B | 5.59B | 6.37B | 8.02B | 8.74B | 9.07B | 9.44B | 9.93B |
| Operating Income | 578M | 633M | 718M | 918M | 1.45B | 1.04B | 1.42B | 1.63B | 1.35B | 2.10B | 2.59B |
| EBITDA | 661M | 728M | 831M | 1.06B | 1.53B | 1.31B | 1.81B | 3.24B | 3.13B | 3.47B | 2.55B |
| Net Income | 430M | 475M | 532M | 703M | 1.06B | 791M | 1.04B | 1.17B | 915M | 1.24B | 1.69B |
| EPS | 0.44 | 0.47 | 0.49 | 0.53 | 0.94 | 0.70 | 0.91 | 1.03 | 0.81 | 1.08 | 1.49 |
| Balance Sheet | |||||||||||
| Total Assets | 3.58B | 5.82B | 6.54B | 8.67B | 12.3B | 17.3B | 20.8B | 24.1B | 26.4B | 26.5B | 27.7B |
| Total Liabilities | 2.24B | 3.02B | 3.45B | 4.34B | 6.76B | 11.4B | 14.0B | 16.2B | 18.3B | 17.8B | 18.8B |
| Shareholders' Equity | 1.32B | 2.75B | 3.04B | 4.24B | 5.38B | 5.48B | 6.21B | 6.82B | 6.90B | 7.37B | 7.60B |
| Cash & Short-term Investments | 668M | 1.08B | 1.33B | 1.72B | 4.44B | 2.90B | 4.59B | 4.46B | 6.23B | 6.51B | 6.24B |
| Total Debt | 409M | 515M | 353M | 329M | 1.40B | 5.28B | 5.93B | 5.44B | 6.32B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 496M | 640M | 874M | 1.71B | 1.95B | 1.55B | 3.76B | 3.17B | 3.11B | 5.35B | - |
| Capital Expenditure | 307M | 669M | 554M | 501M | 792M | 1.29B | 1.03B | 1.80B | 1.48B | 485M | 610M |
| Free Cash Flow | 188M | -28.1M | 319M | 1.21B | 1.16B | 260M | 2.72B | 1.38B | 1.63B | 4.87B | 2.34B |
| Ratios | |||||||||||
| ROE | 32.7% | 17.3% | 17.5% | 16.6% | 19.7% | 14.4% | 16.7% | 17.1% | 13.3% | 16.8% | 22.3% |
| ROA | 12.0% | 8.2% | 8.1% | 8.1% | 8.6% | 4.6% | 5.0% | 4.8% | 3.5% | 4.7% | 6.1% |
| Net Profit Margin | 6.9% | 6.4% | 6.0% | 6.3% | 7.3% | 4.7% | 4.9% | 4.8% | 3.5% | 4.5% | 6.0% |
| Debt to Equity | 0.31x | 0.19x | 0.12x | 0.08x | 0.26x | 0.96x | 0.95x | 0.80x | 0.92x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dashenlin Pharm Grp Co Ltd dividends
- Dividend yield
- 3.24%
- Forward dividend
- 0.82 CNY
- Payout ratio
- 63.3%
- Ex-dividend date
- Oct 19, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 782M | 0.69 | 63.3% |
| 2024 | CNY 753M | 0.67 | 82.3% |
| 2023 | CNY 569M | 0.50 | 48.8% |
| 2022 | CNY 395M | 0.35 | 38.2% |
| 2021 | CNY 527M | 0.46 | 66.6% |
| 2020 | CNY 328M | 0.29 | 30.9% |
| 2019 | CNY 240M | 0.18 | 34.2% |
| 2018 | CNY 263M | 0.24 | 49.4% |
| 2017 | CNY 20.5M | 0.02 | 4.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 9, 2023.
Who owns Dashenlin Pharm Grp Co Ltd
- Insiders 62.94%
- Institutions 12.97%
- Public & others 24.10%
- Shares outstanding 1.18B
- Free float 408M
Dashenlin Pharm Grp Co Ltd company profile
- Company name
- Dashenlin Pharm Grp Co Ltd
- Ticker
- 603233.SHG
- ISIN
- CNE100002RG2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 41,141
- Fiscal year end
- December
- Address
- No. 410-1, Longxi Avenue, Guangzhou, China, 51000
- Phone
- 86 20 8168 9688
- Website
- dslyy.com
About Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. engages in the manufacture, distribution, and retail of pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and tonic herbs, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
Dashenlin Pharm Grp Co Ltd management
7- Mr. Guoqiang KeGM & Director · born 1982
- Mr. Guangzhi PengFinancial Director & Secretary to the Board · born 1982
- Ms. Qun Fei TanDeputy GM & Director · born 1967
- Mr. Hong ChenDeputy General Manager · born 1977
- Ms. Xin JiangDeputy General Manager · born 1970
- Mr. Changcheng ChenDeputy General Manager · born 1984
- Mr. Tuo Ji KeDeputy GM & Director · born 1995